Health Sciences Acquisitions 2 Overview
Valuation check: HSAQ's ROE is -308.3%, below the sector sector average of 11.64%.
Get informed when a big investor buys or sells
+ Follow-308.30%
Return on Equity measures how efficiently a company uses shareholders' equity to generate profits. A higher ROE indicates better profitability relative to equity.
The latest ROE for HSAQ is -308.3%. That is below the sector sector average of 11.64%. Investors often review this figure alongside Health Sciences Acquisitions 2's historical trend and sector peers before judging valuation or financial health.
Against its sector companies, HSAQ currently prints -308.3% for ROE, while the sector average sits near 11.64%. That is roughly 2749.4% below the sector mean. Large gaps often invite a closer look at Health Sciences Acquisitions 2's growth, margins, and balance sheet.
Return on Equity shows how effectively Health Sciences Acquisitions 2 converts resources into returns. At -308.3%, HSAQ may look efficient or underperforming depending on peer benchmarks and trend direction. Pair the percentage with revenue growth and leverage for a fuller health check.
After noting HSAQ's ROE (-308.3%), review year-over-year change, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.
